announces – Page 7 – Zion Tech Group

Morgan Wallen announces new ‘I’m The Problem’ album and 2025 tour. What to know

Morgan Wallen’s three-year evolution from consistent country chart-topper to top-tier Billboard all-genre superstar will continue with a newly announced album and tour for 2025.

Leaning into his police blotter appearances and notoriety of late, the 18-time Billboard Music Award winner and 2024 Country Music Association Entertainer of the Year has entitled his forthcoming project “I’m The Problem.” The project’s release date is forthcoming.

The top performer is also set for a 19-date summer 2025 tour from June to September.

A rotating lineup of guests including Brooks & Dunn, Miranda Lambert, Thomas Rhett and Koe Wetzel join in direct support with Gavin Adcock, Corey Kent, Ella Langley and Anne Wilson as openers across select dates.

Wallen noted via a press statement that “working on new music” inspired a return to the road so swiftly after an 87-date and two-year-long “One Night at A Time” world tour.

How to purchase tickets for Morgan Wallen’s ‘I’m The Problem’ tour

Fans can sign up for the Artist Presale at signup.ticketmaster.com/morganwallen until Jan. 28 at 10 p.m. PST. The presale will begin Jan. 30. Presale start times vary by market. The general on-sale will begin Jan. 31 at 10 a.m. local time at MorganWallen.com.

Wallen’s North American tour starts June 20 at Houston’s NRG Stadium and includes stops in Seattle, Foxborough, Massachusetts and Toronto, Ontario.

A portion of every ticket sold benefits the Morgan Wallen Foundation (MWF), which supports youth programs focusing on sports and music. During the “One Night At A Time” tour, MWF partnered with Mr. Holland’s Opus Foundation to donate $500,000 worth of musical instruments to schools in need across 14 U.S. 2024 stadium touring cities. For more information, please visit morganwallenfoundation.org.

Morgan Wallen performs during his One Night at a Time Tour concert at Nissan Stadium in Nashville, Tenn., Thursday, May 2, 2024.

As a tour prelude, Wallen will also appear at his inaugural Sand In My Boots Festival in Gulf Shores, Alabama, from May 16-18, 2025.

The festival, which sold out in less than two hours of on-sale, will feature headlining sets by Wallen, Post Malone, Brooks & Dunn and HARDY across three days and three nights. Additional guests will include Riley Green, Bailey Zimmerman, T-Pain, Diplo, Wiz Khalifa, The War on Drugs, 2 Chainz, Chase Rice, Three 6 Mafia, 3 Doors Down, Ella Langley, ERNEST, Morgan Wade, Moneybagg Yo and more.

For full details, visit sandinmybootsfest.com.

‘I’m The Problem’

The album’s title track arrives on Jan. 31. It features a crew of frequent Wallen collaborators as songwriters and producers: ERNEST, Ryan Vojtesak, Grady Block and Jamie McLaughlin join the “Last Night” vocalist as writers, while Big Loud affiliated producers Joey Moi and Charlie Handsome are behind the boards.

“I’m The Problem” follows the all-genre Billboard top-five lovestruck, rock-styled ballad “Smile,” his 16th No. 1 country radio hit “Lies Lies Lies” and “Love Somebody,” the first Wallen solo release to debut at No. 1 on the Billboard Hot 100 chart. “Love Somebody” also debuted on 11 charts globally upon release, leading the artist to become the first to achieve three singles simultaneously sitting atop the Billboard Hot 100 and Hot Country Songs charts.

Wallen’s preceding albums “Dangerous: The Double Album” and “One Thing At A Time” recently landed No. 1 and 6 on Billboard’s Top 200 Albums of the 21st Century, respectively. The latter set a record for country albums by sitting atop the Billboard 200 Albums chart for 19 non-consecutive weeks, yielding seven No. 1 country radio singles.

The performer’s chart-topping success has keyed People’s Choice Country and Pollstar award-winning touring acclaim that spanned three months of dates playing for over three million fans worldwide in venues including four dozen stadiums and over in 2023 and 2024. Dates at Knoxville’s Neyland Stadium and Columbus’ Ohio Stadium found Wallen to have the largest weekend attendance ever at both venues.

Morgan Wallen’s ‘I’m The Problem’ tour dates

Wallen’s 19-date tour across North America includes the following dates:

June 20 // NRG Stadium // Houston, TX w/ Corey Kent and Koe Wetzel
June 21 // NRG Stadium // Houston, TX w/ Corey Kent and Koe Wetzel
June 28 // Camp Randall Stadium // Madison, WI w/ Ella Langley and Miranda Lambert
July 11 // Hard Rock Stadium // Miami Gardens, FL w/ Gavin Adcock and Miranda Lambert
July 12 // Hard Rock Stadium // Miami Gardens, FL w/ Gavin Adcock and Brooks & Dunn
July 18 // State Farm Stadium // Glendale, AZ w/ Ella Langley and Miranda Lambert
July 19 // State Farm Stadium // Glendale, AZ w/ Ella Langley and Brooks & Dunn
July 25 // Lumen Field // Seattle, WA w/ Anne Wilson and Miranda Lambert
July 26 // Lumen Field // Seattle, WA w/ Anne Wilson and Brooks & Dunn
Aug 1 // Levi’s Stadium // Santa Clara, CA w/ Anne Wilson and Miranda Lambert
Aug 2 // Levi’s Stadium // Santa Clara, CA w/ Anne Wilson and Brooks & Dunn
Aug 15 // Huntington Bank Field // Cleveland, OH w/ Ella Langley and Miranda Lambert
Aug 16 // Huntington Bank Field // Cleveland, OH w/ Ella Langley and Thomas Rhett
Aug 22 // Gillette Stadium // Foxborough, MA w/ Corey Kent and Miranda Lambert
Aug 23 // Gillette Stadium // Foxborough, MA w/ Corey Kent and Miranda Lambert
Sep 4 // Rogers Centre // Toronto, ON w/ Gavin Adcock and Miranda Lambert
Sep 5 // Rogers Centre // Toronto, ON w/ Gavin Adcock and Brooks & Dunn
Sep 12 // Commonwealth Stadium // Edmonton, AB w/ Ella Langley and Miranda Lambert
Sep 13 // Commonwealth Stadium // Edmonton, AB w/ Ella Langley and Brooks & Dunn

This article originally appeared on Nashville Tennessean: Morgan Wallen new ‘I’m The Problem’ album, 2025 tour: What to know

Country music star Morgan Wallen has just announced his highly anticipated new album titled ‘I’m The Problem’ along with a 2025 tour. The album is set to be released later this year and will feature a mix of new songs that showcase Wallen’s signature sound and storytelling abilities.

In a recent press release, Wallen shared his excitement for the new project, stating, “I’m really proud of this album and the songs on it. It’s a reflection of where I’m at in my life right now and I can’t wait for my fans to hear it.”

The 2025 tour will kick off in the spring and will feature Wallen performing in cities across the country. Fans can expect an energetic and unforgettable live show, complete with all of Wallen’s hits as well as new songs from ‘I’m The Problem.’

Tickets for the tour are set to go on sale soon, so be sure to keep an eye out for updates on Morgan Wallen’s official website and social media channels. Don’t miss your chance to see this talented artist live in concert and experience his music in a whole new way. Get ready for ‘I’m The Problem’ and the 2025 tour – it’s sure to be a can’t-miss event for country music fans everywhere.

Tags:

Morgan Wallen
I’m The Problem
new album
2025 tour
country music
album release
tour dates
country singer
music news
Morgan Wallen tour dates

#Morgan #Wallen #announces #Problem #album #tour

January 24, 2025

Genshin Impact announces a huge change for update 5.5: your custom-made artifacts can’t be absolute trash anymore, so hold onto your Sanctifying Elixirs

Presumably worn down by the cries of disappointed players, the Genshin Impact team announced a legitimately massive quality-of-life update coming in patch 5.5, which is about nine weeks away at the time of writing: custom artifacts crafted by spending Sanctifying Elixir will be “guaranteed” to roll your specified substats at least twice, preventing flat-out garbage pieces.

This change was the footnote (and frankly, also the star) of the Genshin team’s latest developer discussion. “Since the launch of ‘Sanctifying Elixir,’ we have closely monitored all feedback about the resource,” HoYoverse writes. “To provide a better level-up experience for you, we will optimize the mechanics of ‘Sanctifying Elixir’ from Version 5.5 onwards.”

This is, of course, a very nice way to say that we saw y’all falling to pieces in posts and surveys lamenting that your hard-earned, hand-picked artifacts rolled into worthless stats. And, to be fair, that does feel bad. Entire YouTube videos and accounts have been made to chronicle the relatable artifact pain of Genshin content creators like Xiao devotee Zy0x. Sanctifying Elixirs take a long time to get and have the potential to pocket you a great piece of gear, so it hurts even more when that gear ends up completely worthless. Luckily, that won’t be possible anymore.

“Starting from Version 5.5, when using ‘Sanctifying Elixir’ to define Artifacts, the defined ‘Minor Affixes’ will be guaranteed to receive at least 2 enhancements when enhanced to level 20, thus improving your character-building efficiency!” the post adds.

The textbook way to spend Sanctifying Elixir is to pick a rare main stat, like a specific elemental goblet or an elemental mastery sands for your character’s best artifact set, and slap critical rate and damage on that piece. These are simply some of the best and rarest stats you can roll, which is what you want to spend your Elixir on. Beginning with update 5.5, if you craft a piece like that, you’ll always roll into critical rate and damage – that is, the substats you chose – at least two times.

In this double-crit hypothetical, this change would guarantee four rolls (two base and two bonus) of critical stats at level 20. Even in the absolute worst-case scenario, that is at least in the realm of decent. And with two rolls locked in, you’ll have above 50% odds of getting a piece that’s genuinely good. This dramatically raises the floor and improves the odds for crafted artifacts, which should cut down on letdowns and make building characters noticeably easier. Low rolls are still possible, but not quite so low.

To sum it up: don’t craft a single thing until update 5.5. Now, if HoYoverse can just act on all the feedback about Elixirs being too uncommon, we’ll really be in business.

Genshin Impact community rallies to pummel one player “shamelessly admitting that I want friends” with so many friend requests that they can barely respond to everyone.

Genshin Impact fans, get ready for a game-changing update in version 5.5! In a recent announcement, the developers have revealed a major change that will have players rejoicing: custom-made artifacts will no longer be able to be absolute trash.

That’s right, say goodbye to all those disappointing rolls and wasted Sanctifying Elixirs. From now on, your hard-earned artifacts will have a much higher chance of rolling desirable stats and substats, making your characters even more powerful than before.

So start hoarding those Sanctifying Elixirs and get ready to finally create some truly game-changing artifacts in Genshin Impact update 5.5!

Tags:

Genshin Impact, update 5.5, custom-made artifacts, Sanctifying Elixirs, artifact improvement, artifact changes, Genshin Impact news, Genshin Impact updates

#Genshin #Impact #announces #huge #change #update #custommade #artifacts #absolute #trash #anymore #hold #Sanctifying #Elixirs

January 24, 2025

GLAAD ANNOUNCES NOMINEES FOR THE 36th ANNUAL GLAAD MEDIA AWARDS

36th GLAAD Media Awards Logo

The 36th Annual GLAAD Media Awards announced 303 nominees across 33 categories including culture-shifting stories about transgender people, people living with HIV, global LGBTQ criminalization, LGBTQ asylum seekers, LGBTQ youth, and more

LGBTQ stories and creatives across entertainment take center stage with nominees including: “Abbott Elementary,” “Agatha All Along,” “Baby Reindeer,” Billie Eilish, Doechii, Elton John, “Lil Nas X: Long Live Montero,” “My Old Ass,” “RuPaul’s Drag Race,” “Sesame Street,” “Southern Charm,” “The Umbrella Academy,” “Will & Harper,” and “Wicked”

Additional nominees include: The 77th Tony Awards, The 98th Macy’s Thanksgiving Day Parade, “Brilliant Minds,” Cosmopolitan, “Fancy Dance,” “Fantasmas,” “The Kelly Clarkson Show,” “Land of Women,” Michaela Jae, “Palm Royale,” “Primer Impacto,” “The Real Housewives of New York City,”
Victoria Monét, “The View,” and Vogue

In Journalism, local news soars with coverage from Columbus, San Francisco, Spokane, Tulsa and more nominated alongside powerhouse storytelling from The Advocate, Bloomberg TV, CNBC.com, ESPN, MSNBC, The New Yorker, PBS, Telemundo, as GLAAD celebrates newly-expanded category honoring Outstanding Independent Journalism

GLAAD also announced Special Recognition honors for “DRAG: The Musical,” “Red Ink: A Tribute to Cecilia Gentili,” The Stonewall National Monument Visitor Center, OUTLOUD, Q.Digital, and WNBA 2024 Champions, The New York Liberty

The 36th Annual GLAAD Media Awards are presented by official sponsors Delta, Hornitos, and Sony Music Group taking place in Los Angeles on March 27, 2025

New York, New York – Wednesday, January 22, 2025 – GLAAD, the world’s largest lesbian, gay, bisexual, transgender, and queer (LGBTQ) media advocacy organization, today announced the nominees of the 36th GLAAD Media Awards. In a time of unprecedented challenges for LGBTQ people, LGBTQ stories are the antidote to anti-LGBTQ violence, legislation and disinformation.

GLAAD’s mission to accelerate acceptance and understanding for LGBTQ people through visibility in media stands stronger than ever, with the 36th GLAAD Media Awards spotlighting 303 culture-changing nominees across 33 categories, honoring outstanding fair, accurate, and inclusive representations of LGBTQ people and issues in film, television, gaming, publishing, stage productions, music, podcasting, journalism, and more.

Since 1990, the GLAAD Media Awards have grown to be the most visible annual LGBTQ awards show in the world, sending powerful messages of acceptance to audiences globally. Nominees for the 36th Annual GLAAD Media Awards reflect work published, released, or broadcast between January 1 and December 31, 2024.

GLAAD routinely reviews the accuracy and impact of GLAAD Media Awards categories to best reflect the ever-evolving media landscape, including the ways in which media is consumed by audiences and consumers alike. As such, and in recognition of the profusion of news sources in the overall media landscape, this year, GLAAD celebrates the category of Outstanding Blog being updated to Outstanding Independent Journalism. This expanded category will recognize creators and independent news organizations that drive journalism and commentary for and about LGBTQ people and issues.

A tip sheet with a breakdown of nominations by media and trends among the nominees is available HERE and at: www.glaad.org/releases.

Statement by GLAAD President & CEO Sarah Kate Ellis:
“The GLAAD Media Awards were created nearly four decades ago to champion LGBTQ stories amid a deeply hostile and unsafe time for our community. Today, this mission holds true and ever-more important as attacks against LGBTQ people are not only growing, but finding new avenues. Whether it’s rampant misinformation or defamation of transgender people, LGBTQ youth, or the shocking corporate rollback of policies and programs that keep LGBTQ people seen and safe in a workforce, what will always prevail is our truth and talent. This year’s nominees for the 36th GLAAD Media Awards represent the best of our vibrant community, spanning across all media, genres and mediums, and send a loud and global message to industry leaders that our stories are not only popular and entertaining, but necessary and culture-changing.”

ADDITIONAL DETAILS ABOUT THE 36th GLAAD MEDIA AWARDS

The GLAAD Media Awards ceremony, which powers GLAAD’s work to accelerate LGBTQ acceptance and visibility in media all year round, will be held this year in Los Angeles.

GLAAD President and CEO Sarah Kate Ellis serves as Executive Producer of the 36th GLAAD Media Awards, alongside GLAAD’s Rich Ferraro and Anthony Allen Ramos. GLAAD’s Tony Morrison will serve as Supervising Producer and Jose Useche will serve as Producer. The ceremony is produced in partnership with STAMP Event Co.

Tag and follow #GLAADawards and @glaad for updates and reactions from nominees.

The 36th Annual GLAAD Media Awards are presented by: Official Sponsors, Delta Air Lines, Hornitos and Sony Music Group

For more information on how to become a corporate sponsor or to purchase company tables, please contact partnerships@glaad.org

SPECIAL RECOGNITION

Each year, GLAAD presents non-competitive honors to projects across entertainment and media that do not fit into existing or traditional GLAAD Media Awards categories. Spotlighting the strength, resilience and ingenuity of the LGBTQ community, GLAAD has chosen six projects to receive this honor for the 36th GLAAD Media Awards.

For their immeasurable impact and contributions to LGBTQ acceptance and visibility, GLAAD has awarded the Special Recognition honor to: “DRAG: The Musical,” “La Verdrag” (Canal Once), OUTLOUD, “Red Ink: A Tribute to Cecilia Gentili,” The Stonewall National Monument Visitor Center, “The Q Agenda” (LatiNation), and WNBA 2024 Champions: The New York Liberty.

GLAAD’s Barbara Gittings Award for Excellence in LGBTQ Media honors a pioneering individual, group, or community media outlet that has made a significant contribution to the development of LGBTQ media. The award is named after Barbara Gittings in recognition of her groundbreaking work as editor of The Ladder, and for her appearances as an out lesbian on national news media throughout the 1970s and 1980s.

This year, GLAAD’s Barbara Gittings Award for Excellence in LGBTQ Media is presented to: Q.Digital

A full summary of the projects receiving Special Recognition can be found in the tip sheet with an additional breakdown of facts and figures about this year’s nominees available HERE and at: www.glaad.org/releases.

Working journalists may apply for red carpet credentials HERE.

Publicists may apply for red carpet credentials HERE.

The Digital Press Kit, including social media assets for nominees and journalists is HERE

————————————

NOMINEES FOR THE 36TH ANNUAL GLAAD MEDIA AWARDS

Outstanding Film – Wide Theatrical Release

Cuckoo (Neon)
Drive-Away Dolls (Focus Features)
Love Lies Bleeding (A24)
Mean Girls (Paramount Pictures)
My Old Ass (Amazon MGM Studios)
Problemista (A24)
Queer (A24)
Wicked (Universal Pictures)

Outstanding Comedy Series

Abbott Elementary (ABC)
Ghosts (CBS)
Hacks (Max)
Loot (Apple TV+)
The Sex Lives of College Girls (Max)
Shrinking (Apple TV+)
Somebody Somewhere (HBO)
Sort Of (Max)
We Are Lady Parts (Peacock)
What We Do in the Shadows (FX)

Outstanding Drama Series

9-1-1: Lone Star (Fox)
Arcane (Netflix)
The Chi (Showtime)
Doctor Who (Disney+)
Found (NBC)
Heartbreak High (Netflix)
Anne Rice’s Interview with the Vampire (AMC)
Star Trek: Discovery (Paramount+)
The Umbrella Academy (Netflix)
Wicked City (ALLBLK)

Outstanding New Series

Agatha All Along (Disney+)
Black Doves (Netflix)
Brilliant Minds (NBC)
Diarra from Detroit (BET+)
Fantasmas (HBO)
Hazbin Hotel (Amazon Prime Video)
How to Die Alone (Hulu)
Kaos (Netflix)
No Good Deed (Netflix)
Palm Royale (Apple TV+)

Outstanding Film – Streaming or TV

Am I Ok? (Max)
Fancy Dance (Apple TV+)
Good Grief (Netflix)
The Groomsmen: Second Chances (Hallmark)
The Holiday Exchange (Amazon Prime Video / Peacock)
Mother of the Bride (Netflix)
Ricky Stanicky (Amazon Prime Video)
Season’s Greetings from Cherry Lane (Hallmark)
Sweethearts (Max)
Wynonna Earp: Vengeance (Tubi)

Outstanding Documentary

“Breaking the News” Independent Lens (PBS)
“Campbell Addy” Photographer (National Geographic)
Chasing Chasing Amy (Level 33 Entertainment)
Down in the Valley (Starz)
Hidden Master: The Legacy of George Platt Lynes (Greenwich Entertainment)
“Hummingbirds” POV (PBS)
Lil Nas X: Long Live Montero (HBO)
Outstanding: A Comedy Revolution (Netflix)
“Who I am Not” POV (PBS)
Will & Harper (Netflix)

Outstanding Limited or Anthology Series

Baby Reindeer (Netflix)
Becoming Karl Lagerfeld (Disney+)
Carol & The End of the World (Netflix)
Eric (Netflix)
Expats (Amazon Prime Video)
Feud: Capote vs The Swans (FX)
Get Millie Black (Max)
Mary & George (Starz)
The New Look (Apple TV+)
Under the Bridge (Hulu)

Outstanding Film – Limited Theatrical Release

20,000 Species of Bees (Film Movement)
Backspot (XYZ Films)
Before I Change My Mind (Epic Pictures)
Big Boys (Dark Star Pictures)
Close to You (Greenwich Entertainment)
Crossing (MUBI)
Fitting In (Blue Fox Entertainment)
High Tide (Strand Releasing)
Housekeeping for Beginners (Focus Features)
A Place of Our Own (Dark Star Pictures)

Outstanding Reality Program

Bargain Block (HGTV)
Big Freedia Means Business (Fuse)
The Boyfriend (Netflix)
Queer Eye (Netflix)
The Real Housewives of New York City (Bravo)
Selling Sunset (Netflix)
Southern Charm (Bravo)
Wayne Brady: The Family Remix (Freeform)
We’re Here (HBO)
Wiggin’ Out with Tokyo Stylez (We TV)

Outstanding Reality Competition Program

The Amazing Race (CBS)
The Boulet Brothers’ Dragula (Shudder / AMC+)
The Challenge 40: Battle of the Eras (MTV)
Finding Mr. Christmas (Hallmark+)
Hell’s Kitchen: Head Chef’s Only (Fox)
I Kissed a Boy (Hulu)
I Kissed a Girl (Hulu)
RuPaul’s Drag Race (MTV)
Top Chef (Bravo)
The Voice (NBC)

Outstanding Children’s Programming

“Aunt Praline’s Sweetie Pie” Strawberry Shortcake: Berry in the Big City (Paramount+)
The Fairly OddParents: A New Wish (Nickelodeon)
Firebuds (Disney Jr.)
“I’m Pogey” Fraggle Rock: Back to the Rock (Apple TV+)
Let’s Go, Bananas! (Cartoonito)
Monster High (Nickelodeon)
“Our Family Musical” Sesame Street (Max)
“Princess Royal Wedding” Princess Power (Netflix)
Star Wars: Young Jedi Adventures (Disney Jr. / Disney+)
Vida the Vet (Netflix)

Outstanding Kids & Family Programming or Film – Live Action

Empire Waist (Blue Fox Entertainment)
Heartstopper (Netflix)
“If You Love Me” Beyond Black Beauty (Amazon Prime Video)
Jane (Apple TV+)
“Louds in Love” The Really Loud House (Nickelodeon)

Outstanding Kids & Family Programming or Film – Animated

The Bravest Knight (Hulu)
The Dragon Prince (Netflix)
Fright Krewe (Hulu / Peacock)
Kiff: The Haunting of Miss McGravy’s House (Disney Channel)
“I Wanna Dance with My Buddy” Hailey’s On It! (Disney Channel)
Jurassic World: Chaos Theory (Netflix)
The Loud House (Nickelodeon)
Moon Girl and Devil Dinosaur (Disney Channel)
“Powerless” Monsters at Work (Disney Channel)
“Summer of Heart Eyes” Primos (Disney Channel)

Outstanding Music Artist

Adam Lambert, AFTERS (More is More)
Billie Eilish, HIT ME HARD AND SOFT (Darkroom/Interscope)
Doechii, Alligator Bites Never Heal (Top Dawg Entertainment/Capitol Records)
Elton John, Never Too Late: Soundtrack to the Disney+ Documentary (UMG Recordings)
Joy Oladokun, OBSERVATIONS FROM A CROWDED ROOM (Verve Forecast/Republic Records)
Kali Uchis, ORQUÍDEAS (Geffen Records)
Omar Apollo, God Said No (Warner Records)
Orville Peck, Stampede (Warner Records)
Tove Lo, HEAT (Pretty Swede Records)
Victoria Monét, JAGUAR II: Deluxe (Lovett Music/RCA Records)

Outstanding Breakthrough Music Artist

Beabadoobee (Dirty Hit)
The Blessed Madonna (Major Recordings / Warner Record)
Durand Bernarr (DSing Records)
Gigi Perez (Gigi Perez PS/Island)
The Last Dinner Party (Island Records)
Medium Build (Island Records)
Michaela Jaé (TribeDisciples)
Remi Wolf (Island Records)
Villano Antillano (La Buena Fortuna Music)
Young Miko (Wave Music Group/Capitol Records)

Outstanding Broadway Production

Cult of Love, by Leslye Headland
Illinoise, book by Justin Peck, Jackie Sibblies Drury, music and lyrics by Sufjan Stevens
Lempicka, book by Carson Kreitzer, Matt Gold, music by Matt Gould, lyrics by Carson Kreitzer
Mother Play, by Paula Vogel
Oh, Mary!, by Cole Escola

Outstanding Podcast

Baby, This is Keke Palmer (Wondery)
But We Loved (iHeart)
Las Culturistas (iHeart)
Made it Out (Made It Out Media)
Queer West (Audible)
Rooted Recovery Stories (Promises Behavioral Health/The Cast Collective)
“The Science Of Transgender Healthcare, Puberty Blockers, & Conversion Therapy with Dr. Jack Turban” The Checkup with Dr. Mike (DM Operations Inc.)
Sibling Rivalry (Studio 71)
Surface Level
Tres Leches

Outstanding Video Game

Caravan SandWitch (Studio Plane Toast / Dear Villagers)
Dragon Age: The Veilguard (BioWare / Electronic Arts)
Dread Delusion (Lovely Hellplace / DreadXP)
Dustborn (Red Thread Games / Spotlight by Quantic Dream)
Fear the Spotlight (Cozy Game Pals / Blumhouse Games)
Life is Strange: Double Exposure (Deck Nine / Square Enix)
Minds Beneath Us (BearBone Studio)
Paper Mario: The Thousand-Year Door (Intelligent Systems / Nintendo)
Sorry We’re Closed (à la mode games / Akupara Games)
Until Then (Polychroma Games / Maximum Entertainment)

Outstanding Comic Book

Alan Scott: The Green Lantern, by Tim Sheridan, Cian Tormey, Jordi Tarragona, Raúl Fernandez, John Livesay, Matt Herms, Chris Sotomayor, Lucas Gattoni (DC Comics)
Avengers Academy: Marvel’s Voices, by Anthony Oliveira, Carola Borelli, Bailie Rosenlund, IG Guara, Alba Glez, Elisabetta D’Amico, Pablo Collar, Karen S. Darboe, Carlos Lopez, KJ Díaz, Ian Herring, Frank William, Ariana Maher, Joe Caramagna (Marvel Infinity Comics)
Captain Marvel, by Alyssa Wong, Jan Bazaldua, Ruairí Coleman, Roberto Poggi, Bryan Valenza, Carlos Lopez, Ariana Maher (Marvel Comics)
I Heart Skull-Crusher, by Josie Campbell, Alessio Zonno, Angel De Santiago, Jim Campbell (BOOM! Studios)
The Nice House by the Sea, by James Tynion IV, Álvaro Martínez Bueno, Jordie Bellaire, Andworld Design (DC Comics)
NYX, by Jackson Lanzing, Collin Kelly, Francesco Mortarino, Enid Balám, Elisabetta D’Amico, Michael Shelfer, Raúl Angulo, Joe Sabino (Marvel Comics)
The Oddly Pedestrian Life of Christopher Chaos, by Tate Brombal based on an idea by James Tynion IV, Isaac Goodhart, Soo Lee, Naomi Franq, Miquel Muerto, Patricio Delpeche, Héctor Barros, Aditya Bidikar (Dark Horse Comics)
Poison Ivy, by G. Willow Wilson, Marcio Takara, Luana Vecchio, Haining, Arif Prianto, Hassan Otsmane-Elhaou (DC Comics)
Spectregraph, by James Tynion IV, Christian Ward, Aditya Bidikar (DSTLRY)
Suicide Squad: Dream Team, by Nicole Maines, Eddy Barrows, Eber Ferreira, José Luís, Adriano Di Benedetto, Adriano Lucas, Becca Carey (DC Comics)

Outstanding Original Graphic Novel/Anthology

Ash’s Cabin, by Jen Wang (First Second)
Bad Dream: A Dreamer Story, by Nicole Maines, Rye Hickman (DC Comics)
Becoming Who We Are: Real Stories About Growing Up Trans, [anthology] (A Wave Blue World)
Deadendia: The Divine Order, by Hamish Steele (Union Square & Co.)
The Deep Dark, by Molly Knox Ostertag (Graphix)
The Fox Maidens, by Robin Ha (HarperAlley)
Lunar Boy, by Jes Wibowo and Cin Wibowo (HarperAlley)
My Fairy Godfather, by Robert Mailer Anderson, Jon Sack (Fantagraphics)
The Ribbon Skirt, by Cameron Mukwa (Graphix)
The Science of Ghosts, by Lilah Sturges, El Garing, Alitha Martinez, Hassan Otsmane-Elhaou, Jimmy Betancourt (Legendary Comics)

Outstanding Variety or Talk Show Episode

The 77th Tony Awards (CBS)
The 98th Macy’s Thanksgiving Day Parade (NBC)
“Bernie Sanders Rips the Democratic Establishment; Trump Allies Claim Massive Mandate: A Closer Look” Late Night with Seth Meyers (NBC)
“D.C. Woman Turns Childhood Home Into Communal Living For LGBTQ+ Seniors” The Kelly Clarkson Show (syndicated)
“DNA: This is Not My Child / Mom, Why Can’t You Accept Me?” Karamo (syndicated)
“Elliot Page Talks Season 4 of ‘The Umbrella Academy,’ Fighting Anti-LGBTQ Legislation” The View (ABC)
“Laverne Cox Unpacks Anti-LGBTQ+ Legislation, Bullying & Transness for Spirit Day” The Daily Show (Comedy Central)
“Libraries” Last Week Tonight with John Oliver (HBO)
“Queer Teacher Gets a Life-Changing Surprise!” The Jennifer Hudson Show (syndicated)
“A Special Monologue for the Republican in Your Life” Jimmy Kimmel Live (ABC)

Outstanding TV Journalism Segment

“Becoming Che” SC Featured (ESPN)
“Big Gay Football” CBS Sports (CBS)
“Demystifying Trans Identities” (Spectrum News 1 Ohio)
“Pete and Chasten Buttigieg on Fatherhood” CBS News Sunday Morning (CBS)
“Project Asylum: Transgender Asylum Seekers Find Hope Through San Francisco’s LGBTQ Asylum Project” CBS News Bay Area (KPIX-TV CBS 5 Bay Area)
“Small Town in Arkansas a Safe Haven For LGBTQ+ Residents” GMA3 (ABC)
“Spectrum Indigenous Celebrates Pride Month With Two Spirit Powwows” KREM 2 News (KREM-TV CBS 2 Spokane)
“Stonewall House” NBC News Now (NBC)
“Transgender Pastor In California Builds Inclusive Church For LGBTQ+ Community” CBS Mornings (CBS)
“Vogue Realness: Billy Porter & LGBTQIA Community Celebrate Dancer O’Shae Sibley” America In Black (BET+)

Outstanding TV Journalism – Long-Form

“American Problems, Trans Solutions” Local, USA (PBS via WORLD Channel)
“The Cure for HIV” Scripps News Reports (Scripps News)
“Chella Man” It’s Ok to Ask Questions (WMAQ-TV NBC 5 Chicago)
“The Life and Death of Blaze Bernstein” 48 Hours (CBS)
“Proud Legacy: A NY1 Special” (Spectrum News NY1)

Outstanding Live TV Journalism – Segment or Special

“Africa’s Anti-LGBTQ Laws: Impact on Uganda’s Economy, Ghana Wants Bill Accelerated” Horizons Middle East & Africa (Bloomberg Television)
“Algerian Boxer Imane Khelif Names J.K. Rowling and Elon Musk in Cyberbullying Suit” NBC News Now (NBC)
“Democrats are Learning The Wrong Message on Trans Youth” Inside with Jen Psaki (MSNBC)
“Finding Love & Light in Unexpected Places: Small Towns Celebrate Pride Across America” Good Morning America (ABC)
“Ina Fried Talks Imane Khelif” The Saturday/Sunday Show with Jonathan Capehart (MSNBC)
“LGBTQ+ Asylum Seekers flee to U.S. to Save Their Lives” José Díaz-Balart Reports (MSNBC)
“Pride Across America” ABC News Group (ABC)
“Rep. Leigh Finke Discusses Gender Affirming Healthcare with Pamela Brown” CNN Newsroom (CNN)
“Sarah McBride reflects on Becoming First Openly Transgender Person Elected To Congress” PBS NewsHour (PBS)
“Young Voters Could Decide The 2024 Election” The 11th Hour with Stephanie Ruhle (MSNBC)

Outstanding Print Article

“After Trump’s Election Win, Local Trans Community Concerned About Their Future” by DeAsia Paige (The Atlanta Journal Constitution)
“‘Changing The Narrative’: Advocates Fight HIV Stigma in Dallas’ Latino Community” by Abraham Nudelstejer (The Dallas Morning News)
“‘I Want To Exist’: Three Days at a Texas Summer Camp for LGBTQ Kids.” by Erin Allday (San Antonio Express-News / San Francisco Chronicle)
“Joe Locke on ‘Heartstopper’ Embracing Sex, Being a Queer Marvel Star in ‘Agatha’ and Why ‘There Are Days I Never Want to Play a Gay Character Again’” by Adam B. Vary (Variety)
“Meet the Young Transgender Teens Changing America and the World” by Ryan Adamczeski (The Advocate)
“Noah J. Ricketts Brings the Bluegrass to Hollywood and Broadway” by Spencer Jenkins (Queer Kentucky)
“Opinion: Celebrating 10 Years of Marriage Equality, More LGBTQ+ History Left to Write” by Josiah Robinson (Tulsa World)
“Our Queerest Century” [special project] (Los Angeles Times)
“Paris Olympics: More Queer Athletes, More Medals, More Pride, Less Grindr” by Dawn Ennis (Washington Blade)
“Sasha Velour Sashays Into The Culture Wars” by Maura Judkis (The Washington Post)

Outstanding Magazine Overall Coverage

The Advocate
Allure
Cosmopolitan
The Hollywood Reporter
Metro Weekly
OUT
People
Plus
Variety
Vogue

Outstanding Online Journalism Article

“Afraid Your Child Will Regret Their Transition? Let’s Talk About It!” by Ben V. Greene (Romper.com)
“CeCé Telfer Was Barred From Competing at The 2024 Paris Olympics as a Trans Woman Athlete. She Has Her Sights Set On L.A. In 2028.” by David Artavia (Yahoo.com)
“First They Tried to ‘Cure’ Gayness. Now They’re Fixated on ‘Healing’ Trans People.” by Madison Pauly with Henry Carnell (MotherJones.com)
“Fleeing the Country and Rationing Testosterone: Transgender Americans’ New Reality Under a Trump Presidency” by Beth Greenfield (Fortune.com)
“Friends Remember Nex Benedict, Oklahoma Student Who Died After School Fight, as ‘Fiery Kid’” by Jo Yurcaba (NBCNews.com)
“He’s 23 and in an Ohio Prison for Exposing Someone to HIV – Even Though He Couldn’t Transmit the Virus” with Ken Schneck/Rachel Dissell (TheBuckeyeFlame.com/TheMarshallProject.com)
“Missouri Republican’s Antigay Slur-Filled Posts Remain on Instagram Despite Violating Meta’s Policies” by Christopher Wiggins (Advocate.com)
“Thailand Could Soon Legalize Same-Sex Marriage. It Would Change Lives.” by Rebecca Root (them.us)
“These Trans People And Their Families Can’t Afford To Flee To A Friendlier State” by Nico Lang (HuffPost.com)
“Your Guide to Accessing Gender-Affirming Care” by Madison Feller (Elle.com)

Outstanding Online Journalism – Video or Multimedia

“Ballin’ Out” (OutSports.com)
“The Legacy of Cecilia Gentili: First Pride Without Mother” (Time.com)
“A Life In Fear: The Dangers Of Finding Love Online As A Queer Woman In Nigeria” (CNN.com)
“Love to the Max: Family Bonds Protect a Trans Teen in Texas” (NewYorker.com)
“The Past, Present, and Future of Trans Visibility in Fashion” (InStyle.com)
“Rainbow Girls: 10 Years of Protection and Prejudice” The Picture Show (NPR.org)
“RuPaul, Tina Knowles, Billy Eichner & More Give Ts Madison Her Flowers” (LogoTV.com)
“The Uncertain Future Of A Historic LGBTQ+ Safe Space: New York City’s People’s Beach” (ABCNews.com)
“War On Woke: How a Gay Rights Index Once Touted By Walmart And Others Became a Conservative Target” (CNBC.com)
“Seat 31: Zooey Zephyr” (NewYorker.com)

Outstanding Independent Journalism

The 19th
Assigned Media
The Buckeye Flame
The Don Lemon Show
Erin in the Morning
Gaye Magazine
Queer News Daily
The Queer Review
TransLash Media
Under the Desk News

Special Recognition

“DRAG: The Musical”
OUTLOUD
Q.Digital
“Red Ink: A Tribute to Cecilia Gentili”
The Stonewall National Monument Visitor Center
The New York Liberty

SPANISH-LANGUAGE CATEGORIES

CATEGORÍAS EN ESPAÑOL

Serie de televisión con guión sobresaliente (Outstanding Scripted Television Series)

Cris Miró (Max)
Land of Women (Apple TV+)
Nadie nos va a extrañar (Amazon Prime Video)
El secreto del río (Netflix)
Vestidas de azul (Atresplayer)

Periodismo televisivo sobresaliente (Outstanding TV Journalism)

“Un Amor de Impacto” Primer Impacto (Univision)
“Esta es la historia de ‘Miss Gaviota’, la primera luchadora trans de México” Noticias Telemundo (Telemundo)
“‘En Honduras nos matan’: estas mujeres transgénero huyeron de persecuciones” Noticias Telemundo (Telemundo)
“Más Allá de los Pronombres” Noticias Telemundo Colorado (Telemundo Colorado)
“Ojo Crítico: Nava Mau’” Showbiz (CNN en Español)

Artículo sobresaliente de periodismo digital (Outstanding Online Journalism Article)

“Así se desmontan los argumentos de una persona TERF” por Aitana Villegas (Huffingtonpost.es)
“Cuando cambiar de nombre es todo un reto: la lucha de las infancias trans en México” por Alicia Fábregas (ElPais.com)
“Estudio lo confirma: jóvenes LGBTQ+ en Puerto Rico son más propensos al acoso, la depresión, ideación e intentos suicidas” por David Cordero Mercado (ElNuevoDia.com)
“Frida Cartas: “Yo no salí del clóset, salí del útero de mi madre y años más tarde tuve que autoparirme sola” por Diana Massis (BBC Mundo)
“Jóvenes latinos gay ven un porcentaje creciente de nuevos casos de VIH en EEUU” por Vanessa G. Sánchez, Phillip Reese y Devna Bose (Univision.com & APNews.com)
“Los líderes emberá LGBTI que resisten a las terapias de conversión y a las amenazas de los paramilitares” por Daniela Díaz (ElPais.com)
“Mujeres trans en deportes: cuando lo más importante es poder competir” por Oscar Bermeo Ocaña* (Sentiido.com)
“Señales de retroceso para la comunidad LGBTQ de Argentina bajo el nuevo gobierno de Javier Milei” por Debora Rey (The Associated Press y El Nuevo Día)
“Sindicalista y mujer trans: esta es la historia de Maura Alzate” por Mariana Escobar Bernoske (ElEspectador.com)
“‘Trump quiere borrarnos’: la lucha por los derechos de la comunidad LGBTQ resuena en la convención demócrata” por Albinson Linares (Telemundo.com)

Periodismo digital sobresaliente – video o multimedia (Outstanding Online Journalism – Video or Multimedia)

“Una cena con Ana y Virginia: Navidad fuera del clóset, con tu familia y en pareja” por Alejandra Ortiz Molano y Catalina Mesa Urquijo (La Disidencia – El Espectador)
“Derechos de las diversidades sexuales en Colombia” por Juan Camilo Arias, Edwin Rodríguez Oliveros, Sergio Rozo, Sandra Lucía Molano Torres, Joan Sebastián Ocampo, Juliana Aragón Echeverry, Juan Camilo Arias, Tatiana Rentería y María Clara Quiroz Arango (El Espectador)
“Derechos LGBTIQ+ en Latinoamérica: retrocesos en países a la vanguardia y orgullo por las conquistas” por Manuela Cano Pulido (Ellas Hoy – France 24 Español)
“La investigadora que buscaba su identidad” por Natalia Orozco, Cristina Gleinig y Carlos Delgado (Fuerza Latina – DW Español)
“El Orgullo Es Universal” por Rigo Villalobos y Aline González Basalo (Telemundo 20 San Diego)

Reconocimiento Especial /Special Recognition

“The Q Agenda” (LatiNation)
“La Verdrag” (Canal Once)

————————————————

Working journalists may apply for red carpet credentials HERE.

Publicists may apply for red carpet credentials HERE.

The Digital Press Kit, including social media assets for nominees and journalists is HERE

GLAAD ANNOUNCES NOMINEES FOR THE 36th ANNUAL GLAAD MEDIA AWARDS

The Gay & Lesbian Alliance Against Defamation (GLAAD) has officially announced the nominees for the 36th Annual GLAAD Media Awards, which honor media for fair, accurate, and inclusive representations of the LGBTQ+ community.

This year’s nominees include a diverse range of television shows, films, and media outlets that have made significant strides in representing LGBTQ+ characters and storylines. Some of the standout nominees include the groundbreaking series “Pose,” the critically acclaimed film “Booksmart,” and the hit show “Schitt’s Creek.”

GLAAD President and CEO Sarah Kate Ellis expressed her excitement about this year’s nominees, stating, “This year’s nominees truly represent the best of LGBTQ representation in media, and we are thrilled to honor their outstanding contributions to our community.”

The winners of the 36th Annual GLAAD Media Awards will be announced at a ceremony in New York City on March 19, 2021, and in Los Angeles on April 16, 2021. Stay tuned for updates on the winners and be sure to support and celebrate LGBTQ+ representation in media.

Tags:

GLAAD Media Awards, GLAAD nominees, LGBTQ+ representation, media recognition, 36th Annual GLAAD Awards, LGBTQ+ advocacy, diversity in media, GLAAD winners, inclusive storytelling

#GLAAD #ANNOUNCES #NOMINEES #36th #ANNUAL #GLAAD #MEDIA #AWARDS

January 24, 2025

‘Mamba and Mambacita Forever’: Vanessa Bryant announces mural book honoring Kobe and Gianna

SUGGESTED: Vanessa Bryant announces Kobe’s statue unveiling ceremony for early 2024

SUGGESTED: The statue will be unveiled on Feb. 8, 2024. (Twitter/X: Los Angeles Lakers)

LOS ANGELES – On Wednesday, Vanessa Bryant announced the release date of a book that will honor the legacies of her late husband and daughter.

“Mamba and Mambacita Forever” will be released on August 19, 2025, which comes during Mamba Week, a week-long celebration dedicated to honoring Kobe Bryant. The week also includes Kobe Bryant Day and the late NBA icon’s heavenly birthday.

Kobe Bryant and daughter Gianna Bryant. (Photo by Harry How/Getty Images) (Getty Images)

The book will highlight a selection of murals in their honor, Vanessa Bryant explained in an Instagram caption.

Vanessa Bryant authored the book while the photos were taken by Andy Bernstein.

In addition to keeping Kobe and Gigi’s legacies alive, Vanessa Bryant has been instrumental in philanthropic efforts on behalf of the Mamba and Mambacita Foundation.

SUGGESTED:

Amid the devastation of the LA wildfires, the foundation donated clothes and shoes to children impacted by the fires.

Sunday, Jan. 26 marks five years since nine lives were lost in a horrific helicopter crash. Kobe and Gianna “Gigi” Bryant, along with her teammates and their parents, were on their way to a basketball tournament when their helicopter crashed into the Santa Monica Mountains on what was a foggy morning in Los Angeles. There were no survivors.

Kobe Bryant Los Angeles Lakers Instastories

Vanessa Bryant, wife of the late Kobe Bryant, has announced the release of a special mural book titled “Mamba and Mambacita Forever” in honor of her husband and daughter Gianna.

The book will feature a collection of murals dedicated to Kobe and Gianna, showcasing the impact they had on the world both on and off the basketball court. Vanessa shared the news on social media, expressing her gratitude for the outpouring of love and support from fans around the globe.

The Bryant family has been working closely with artists and photographers to curate a beautiful tribute to Kobe and Gianna, highlighting their legacy and inspiring future generations. The book will serve as a lasting memory of the father-daughter duo, celebrating their bond and the positive influence they had on so many lives.

Vanessa hopes that “Mamba and Mambacita Forever” will bring comfort to fans who continue to mourn the loss of Kobe and Gianna, while also serving as a reminder of their enduring spirit and resilience. The book is set to be released later this year, with proceeds going towards the Mamba & Mambacita Sports Foundation, which supports youth sports programs in underserved communities.

As the world continues to remember and honor Kobe and Gianna, Vanessa Bryant’s dedication to preserving their legacy through this mural book is a heartfelt gesture that will surely touch the hearts of fans everywhere. Mamba and Mambacita will indeed live on forever.

Tags:

Mamba and Mambacita Forever
Vanessa Bryant
Kobe Bryant
Gianna Bryant
Mural book
Honoring Kobe and Gianna
Kobe and Gianna tribute
Vanessa Bryant announcement
Kobe Bryant legacy
Mamba mentality
Bryant family
Basketball legends
Black Mamba
Mambacita
Kobe and Gianna mural
Vanessa Bryant news
Kobe Bryant memorial
Legacy of Kobe and Gianna

#Mamba #Mambacita #Vanessa #Bryant #announces #mural #book #honoring #Kobe #Gianna

January 24, 2025

Lady Vol head coach Kim Caldwell announces birth of first child

Tennessee Lady Vol coach Kim Caldwell is not with the team in Texas and will not coach tonight following the birth of her first child. Tennessee announced on Thursday Coach Caldwell and her husband Justin have welcomed the arrival of their son Conor Scott Caldwell.

Caldwell has been mum on the plan to manage her team in her absence.

When asked last week about how things would work, Caldwell said there was one and left it at that.

“(I’m) due any day now and we have a plan, but I’m not going to share it,” Caldwell said.

Caldwell coached Sunday in Nashville her Lady Vol team fell to Vanderbilt 71-70 as the Commodores made the game winning shot on an offensive rebound.

Caldwell, who sources said had some hopes of not missing a game is likely to return to the bench on Monday night when the Lady Vols host South Carolina, but has made it clear the entire pregnancy that it was out of her hands.

“I think that I’ve probably looked at our schedule a thousand times and tried to plan it out, but God’s got it and you take it day by day,” Caldwell said on the Sports Animal back in September after announcing her pregnancy on X on September 3. “And you put your faith that God will take care of it and he gave you this blessing for a reason, and that’s what we’re going to do. We have a great staff, a great support system, a great team, so it’s going to be — it’s going to be just fine.”

In Caldwell’s absence Thursday night, assistant Jenna Burdette is taking the lead coaching chair but said in her media session on Tuesday that it would be a collaborative effort.

“Our staff, we work very well together. We are all coaching on the floor especially in practice we all have our certain areas of expertise that we really look into. We are all kind of different in a way that we all kind of focus on different things. It will be a collective effort,” Burdette explained.

Burdette, who was with Caldwell at Glenville State and Marshall, recorded Caldwell’s TV show in her place late last week and did Caldwell’s post game radio show Sunday in Nashville. Caldwell has made it clear that she plans to return to the bench as early as possible but has stated from the beginning of the pregnancy that the timetable for her return is out of her hands.

Following the South Carolina game, the Lady Vols are off till Sunday, Feb. 2nd when they play at Missouri.

The Lady Vols are 15-3 on the season and are 3-3 in SEC play after Sunday’s loss at Vanderbilt.

Lady Vol head coach Kim Caldwell is thrilled to announce the birth of her first child, a beautiful baby girl named Lily. Caldwell and her husband, Jake, welcomed their bundle of joy into the world earlier this week and are overjoyed with the newest addition to their family.

Caldwell, who has been coaching the Lady Vols for the past five years, took to social media to share the exciting news with fans and supporters. She expressed her gratitude for the outpouring of love and well wishes from the Tennessee community and assured everyone that she and Lily are both healthy and happy.

As she embarks on this new chapter of motherhood, Caldwell is grateful for the support of her coaching staff, players, and colleagues at the University of Tennessee. She is looking forward to balancing her responsibilities as a head coach with the joys of raising her daughter and is excited for the journey ahead.

Join us in congratulating Coach Caldwell and her family on this special occasion. Welcome to the world, Lily! #LadyVols #NewMom #BabyGirl

Tags:

Lady Vol head coach Kim Caldwell
Kim Caldwell
Lady Vol
Head coach
Birth announcement
First child
Tennessee
University of Tennessee
Women’s basketball
SEC coach

#Lady #Vol #coach #Kim #Caldwell #announces #birth #child

January 24, 2025

Intuitive Announces Fourth Quarter Earnings

SUNNYVALE, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2024.

Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release.

Fourth quarter 2024 revenue was $2.41 billion, an increase of 25% compared with $1.93 billion in the fourth quarter of 2023. The higher fourth quarter revenue was driven by growth in da Vinci procedure volume and an increase in the installed base of systems.

Fourth quarter 2024 instruments and accessories revenue increased by 23% to $1.41 billion, compared with $1.14 billion in the fourth quarter of 2023. The increase in instruments and accessories revenue was primarily driven by approximately 18% growth in da Vinci procedure volume, approximately 70% growth in Ion procedure volume, and customer buying patterns.

Fourth quarter 2024 systems revenue was $655 million, compared with $480 million in the fourth quarter of 2023. The higher systems revenue, in part, reflected a lower mix of leased systems relative to previous periods as well as higher da Vinci system average selling prices compared with the fourth quarter of 2023. The Company placed 493 da Vinci surgical systems, of which 174 were da Vinci 5 systems, in the fourth quarter of 2024, compared with 415 systems in the fourth quarter of 2023. The fourth quarter 2024 da Vinci surgical system placements included 222 systems placed under operating lease arrangements, of which 140 systems were placed under usage-based operating lease arrangements, compared with 201 systems placed under operating lease arrangements, of which 109 systems were placed under usage-based operating lease arrangements in the fourth quarter of 2023.

Fourth quarter 2024 GAAP income from operations increased to $735 million, compared with $450 million in the fourth quarter of 2023. Fourth quarter 2024 GAAP income from operations included share-based compensation expense of $180 million, compared with $152 million in the fourth quarter of 2023. Fourth quarter 2024 non-GAAP* income from operations increased to $928 million, compared with $621 million in the fourth quarter of 2023.

Fourth quarter 2024 GAAP net income attributable to Intuitive Surgical, Inc. was $686 million, or $1.88 per diluted share, compared with $606 million, or $1.69 per diluted share, in the fourth quarter of 2023. Fourth quarter 2024 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $34 million, or $0.09 per diluted share, compared with $22 million, or $0.06 per diluted share, in the fourth quarter of 2023. Fourth quarter 2023 GAAP net income attributable to Intuitive Surgical, Inc. also included income tax benefits arising from the re-measurement of our Swiss deferred tax assets of $67 million, or $0.19 per diluted share, and the receipt of certain tax assets by our Swiss entity of $92 million, or $0.26 per diluted share. These benefits were excluded from non-GAAP net income. Additionally, fourth quarter 2024 GAAP net income attributable to Intuitive Surgical, Inc. included a discrete tax benefit of $19 million, or $0.05 per diluted share, arising from the release of unrecognized tax benefits due to statute expiration in various jurisdictions, compared with $23 million, or $0.06 per diluted share, in the fourth quarter of 2023.

Fourth quarter 2024 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $805 million, or $2.21 per diluted share, compared with $574 million, or $1.60 per diluted share, in the fourth quarter of 2023. Fourth quarter non-GAAP* net income included a discrete tax benefit of $8 million, or $0.02 per diluted share, arising from the release of unrecognized tax benefits due to statute expiration in various jurisdictions, compared with $23 million, or $0.06 per diluted share in the fourth quarter of 2023, respectively.

The Company ended the fourth quarter of 2024 with $8.83 billion in cash, cash equivalents, and investments, an increase of $521 million during the quarter, primarily driven by cash generated from operations, partially offset by capital expenditures.

2025 Financial Outlook

The Company expects the following results for the full year of 2025:

The Company expects worldwide da Vinci procedures to increase approximately 13% to 16% in 2025 as compared to 2024. Worldwide da Vinci procedure growth was 17% in 2024 as compared to 2023.
The Company expects non-GAAP* gross profit margin to be within a range of 67% and 68% of net revenue in 2025, compared to 69.1% in 2024. This range does not include any potential impact of new tariffs on our business, which could be material.
The Company expects non-GAAP* operating expense growth to be within a range of 10% to 15% in 2025, compared to 10% in 2024.

The 2025 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including but not limited to legal proceedings, without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to Intuitive’s results computed in accordance with GAAP. For additional information regarding the nature of these items, refer to the reconciliations of historical GAAP to non-GAAP measures included elsewhere in this release.

Impact of COVID-19 Pandemic

During 2024, the Company did not experience noticeable procedure volume disruptions due to COVID-19. During the first quarter of 2023, in January, the Company saw COVID-19 resurgences impact da Vinci procedure volumes in China, with a recovery during February and March. The Company also believes that a large portion of the patients in the backlog that required treatment during the COVID-19 pandemic were treated in 2023 and prior and, therefore, the impact of patient backlog was immaterial to procedure volumes in 2024.

Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at https://isrg.gcs-web.com/.

Webcast and Conference Call Information

Intuitive will hold a teleconference at 1:30 p.m. PST today to discuss the fourth quarter 2024 financial results. The call will be webcast live and can be accessed on Intuitive’s website at www.intuitive.com. For those individuals planning to participate on the call, registration can be completed online at https://register.vevent.com/register/BI19317b7619544e91862e6c29f4b0492e to receive dial-in details and an individual pin. The webcast replay of the call will be made available on our website at www.intuitive.com within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.

About Intuitive

Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.

Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owner. See www.intuitive.com/trademarks.

For more information, please visit the Company’s website at www.intuitive.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to the following: statements related to future results of operations, including expected procedure growth in 2025, expected non-GAAP gross profit margins in 2025, and expected non-GAAP operating expense growth in 2025; future financial position; the adoption by customers of the Company’s products; and the goals it shares with its customers, including improving patient outcomes. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which may impact customer spending and the Company’s costs, including tariffs, the levels of inflation, and interest rates; the conflict between Ukraine and Russia; conflicts in the Middle East; disruption to the Company’s supply chain, including difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the U.S. Food and Drug Administration (“FDA”), comparable regulatory authorities, or notified bodies; the risk of the Company’s inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company’s completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; risks associated with the Company’s operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company’s reliance on sole- and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements (including potential new tariffs imposed by the current U.S. presidential administration on imports from Mexico, where we currently manufacture a significant majority of our instruments); and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as updated by the Company’s other filings with the Securities and Exchange Commission. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

*About Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), the Company uses the following non-GAAP financial measures: non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP net income per diluted share attributable to Intuitive Surgical, Inc. (“EPS”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

The Company uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance by excluding items such as amortization of intangible assets, share-based compensation (“SBC”) and long-term incentive plan expenses, and other special items. Long-term incentive plan expense relates to phantom share awards granted in China by the Company’s Intuitive-Fosun joint venture to its employees that vest over four years and can remain outstanding for seven to ten years. These awards are valued based on certain key performance metrics. Accordingly, they are subject to significant volatility based on the performance of these metrics and are not tied to performance of the Company’s business within the period. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to its historical performance. The Company believes these non-GAAP financial measures are useful to investors, because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the Company’s business.

Non-GAAP gross profit. The Company defines non-GAAP gross profit as gross profit, excluding SBC and long-term incentive plan expenses and amortization of intangible assets.

Non-GAAP income from operations. The Company defines non-GAAP income from operations as income from operations, excluding SBC and long-term incentive plan expenses, amortization of intangible assets, a facilities asset abandonment charge, litigation charges and recoveries, and gains on the sale of a business.

Non-GAAP net income attributable to Intuitive Surgical, Inc. and EPS. The Company defines non-GAAP net income as net income attributable to Intuitive Surgical, Inc., excluding SBC and long-term incentive plan expenses, amortization of intangible assets, a facilities asset abandonment charge, litigation charges and recoveries, gains on the sale of a business, gains and losses on strategic investments, tax adjustments, including the excess tax benefits or deficiencies associated with SBC arrangements, a one-time tax benefit from re-measurement of Swiss deferred tax assets, a one-time tax benefit from receipt of certain tax assets by the Company’s Swiss entity, and the net tax effects related to intra-entity transfers of non-inventory assets, and adjustments attributable to noncontrolling interest in joint venture, net of the related tax effects. The Company excludes the excess tax benefits or deficiencies associated with SBC arrangements as well as the tax effects associated with non-cash amortization of deferred tax assets related to intra-entity non-inventory transfers, because the Company does not believe these items correlate with the ongoing results of its core operations. The tax effects of the non-GAAP items are determined by applying a calculated non-GAAP effective tax rate, which is commonly referred to as the with-and-without method. Without excluding these tax effects, investors would only see the gross effect that these non-GAAP adjustments had on the Company’s operating results. The Company’s calculated non-GAAP effective tax rate is generally higher than its GAAP effective tax rate. The Company defines non-GAAP EPS as non-GAAP net income attributable to Intuitive Surgical, Inc. divided by diluted shares outstanding, which are calculated as GAAP weighted-average outstanding shares plus dilutive potential shares outstanding during the period.

There are a number of limitations related to the use of non-GAAP measures versus measures calculated in accordance with GAAP. Non-GAAP gross profit, non-GAAP income from operations, non-GAAP net income attributable to Intuitive Surgical, Inc., and non-GAAP EPS exclude items such as SBC and long-term incentive plan expenses, amortization of intangible assets, excess tax benefits or deficiencies associated with SBC arrangements, and non-cash amortization of deferred tax assets related to intra-entity transfer of non-inventory assets, which are primarily recurring items. SBC expense has been, and will continue to be for the foreseeable future, a significant recurring expense in the Company’s business. In addition, the components of the costs that the Company excludes in its calculation of non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS may differ from the components that its peer companies exclude when they report their results of operations. Management addresses these limitations by providing specific information regarding the GAAP amounts excluded from non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS and evaluating non-GAAP net income attributable to Intuitive Surgical, Inc. and non-GAAP EPS together with net income attributable to Intuitive Surgical, Inc. and net income per share attributable to Intuitive Surgical, Inc. calculated in accordance with GAAP.


INTUITIVE SURGICAL, INC. UNAUDITED QUARTERLY CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA)

	Three Months Ended
	December 31, 2024			September 30, 2024			December 31, 2023
Revenue:
Instruments and accessories	$	1,411.5		$	1,264.2		$	1,143.7
Systems		654.6			445.0			480.2
Services		347.4			328.9			304.4
Total revenue		2,413.5			2,038.1			1,928.3
Cost of revenue:
Product		663.9			555.4			561.3
Service		107.4			108.8			89.6
Total cost of revenue		771.3			664.2			650.9
Gross profit		1,642.2			1,373.9			1,277.4
Operating expenses:
Selling, general and administrative (1)		612.6			510.6			567.1
Research and development		294.7			286.0			260.1
Total operating expenses		907.3			796.6			827.2
Income from operations (2)		734.9			577.3			450.2
Interest and other income (expense), net		74.9			93.7			65.7
Income before taxes		809.8			671.0			515.9
Income tax expense (benefit) (3)		121.8			100.4			(94.8	)
Net income		688.0			570.6			610.7
Less: net income attributable to noncontrolling interest in joint venture		2.3			5.5			4.5
Net income attributable to Intuitive Surgical, Inc.	$	685.7		$	565.1		$	606.2
Net income per share attributable to Intuitive Surgical, Inc.:
Basic	$	1.92		$	1.59		$	1.72
Diluted (4)	$	1.88		$	1.56		$	1.69
Weighted average shares outstanding:
Basic		356.4			355.8			352.1
Diluted		363.9			362.7			358.2

(1) Selling, general and administrative includes the effect of the following item:
Contribution to the Intuitive Foundation	$	45.0		$	—		$	40.0
(2) Income from operations includes the effect of the following items:
Amortization of intangible assets	$	(3.1	)	$	(3.5	)	$	(5.1	)
Expensed IP charged to R&D	$	(5.7	)	$	—		$	(2.0	)
(3) Income tax expense includes the effect of the following items:
One-time tax benefit from re-measurement of Swiss deferred tax assets	$	—		$	—		$	(67.1	)
One-time tax benefit from receipt of certain tax assets by our Swiss entity	$	—		$	—		$	(92.3	)
Excess tax benefits related to share-based compensation arrangements	$	(34.3	)	$	(42.2	)	$	(21.7	)
Discrete tax benefit from release of unrecognized tax benefits	$	(18.9	)	$	(7.5	)	$	(22.8	)
(4) Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:
Contribution to the Intuitive Foundation, net of tax	$	(0.10	)	$	—		$	(0.09	)
Amortization of intangible assets, net of tax	$	(0.01	)	$	(0.01	)	$	(0.01	)
Expensed IP charged to R&D, net of tax	$	(0.01	)	$	—		$	—
One-time tax benefit from re-measurement of certain deferred tax assets	$	—		$	—		$	0.19
One-time tax benefit from receipt of certain tax assets by our Swiss entity	$	—		$	—		$	0.26
Excess tax benefits related to share-based compensation arrangements	$	0.09		$	0.12		$	0.06
Discrete tax benefit from release of unrecognized tax benefits	$	0.05		$	0.02		$	0.06

INTUITIVE SURGICAL, INC. UNAUDITED TWELVE MONTHS ENDED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (IN MILLIONS, EXCEPT PER SHARE DATA)

	Twelve Months Ended
	December 31,
		2024			2023
Revenue:
Instruments and accessories	$	5,079.0		$	4,276.6
Systems		1,966.0			1,679.7
Services		1,307.1			1,167.8
Total revenue		8,352.1			7,124.1
Cost of revenue:
Product		2,313.1			2,041.8
Service		404.8			352.8
Total cost of revenue		2,717.9			2,394.6
Gross profit		5,634.2			4,729.5
Operating expenses:
Selling, general and administrative (1)		2,140.0			1,963.9
Research and development		1,145.3			998.8
Total operating expenses		3,285.3			2,962.7
Income from operations (2)		2,348.9			1,766.8
Interest and other income, net		324.9			192.1
Income before taxes		2,673.8			1,958.9
Income tax expense (3)		336.3			141.6
Net income		2,337.5			1,817.3
Less: net income attributable to noncontrolling interest in joint venture		14.9			19.3
Net income attributable to Intuitive Surgical, Inc.	$	2,322.6		$	1,798.0
Net income per share attributable to Intuitive Surgical, Inc.:
Basic	$	6.54		$	5.12
Diluted (4)	$	6.42		$	5.03
Weighted average shares outstanding:
Basic		355.2			351.2
Diluted		362.0			357.4

(1) Selling, general and administrative includes the effect of the following item:
Contribution to the Intuitive Foundation	$	45.0		$	40.0
(2) Income from operations includes the effect of the following items:
Amortization of intangible assets	$	(16.7	)	$	(20.2	)
Expensed IP charged to R&D	$	(5.9	)	$	(11.0	)
(3) Income tax expense includes the effect of the following items:
One-time tax benefit from re-measurement of Swiss deferred tax assets	$	—		$	(67.1	)
One-time tax benefit from receipt of certain tax assets by our Swiss entity	$	—		$	(92.3	)
Excess tax benefits related to share-based compensation arrangements	$	(223.3	)	$	(107.9	)
Discrete tax benefit from release of unrecognized tax benefits	$	(27.0	)	$	(22.8	)
(4) Diluted net income per share attributable to Intuitive Surgical, Inc. includes the effect of the following items:
Contribution to the Intuitive Foundation, net of tax	$	(0.10	)	$	(0.09	)
Amortization of intangible assets, net of tax	$	(0.04	)	$	(0.04	)
Expensed IP charged to R&D, net of tax	$	(0.01	)	$	(0.02	)
One-time tax benefit from re-measurement of Swiss deferred tax assets	$	—		$	0.19
One-time tax benefit from receipt of certain tax assets by our Swiss entity	$	—		$	0.26
Excess tax benefits related to share-based compensation arrangements	$	0.62		$	0.30
Discrete tax benefit from release of unrecognized tax benefits	$	0.07		$	0.06

INTUITIVE SURGICAL, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (IN MILLIONS)

	December 31, 2024		December 31, 2023
Cash, cash equivalents, and investments	$	8,832.4	$	7,343.2
Accounts receivable, net		1,225.4		1,130.2
Inventory		1,487.2		1,220.6
Property, plant, and equipment, net		4,646.6		3,537.6
Goodwill		347.5		348.7
Deferred tax assets		1,045.1		910.5
Other assets		1,159.0		950.7
Total assets	$	18,743.2	$	15,441.5

Accounts payable and other liabilities	$	1,690.7	$	1,552.5
Deferred revenue		522.9		491.7
Total liabilities		2,213.6		2,044.2
Stockholders’ equity		16,529.6		13,397.3
Total liabilities and stockholders’ equity	$	18,743.2	$	15,441.5

INTUITIVE SURGICAL, INC. UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (IN MILLIONS, EXCEPT PER SHARE DATA)

	Three Months Ended									Twelve Months Ended
	December 31, 2024			September 30, 2024			December 31, 2023			December 31, 2024			December 31, 2023
GAAP gross profit	$	1,642.2		$	1,373.9		$	1,277.4		$	5,634.2		$	4,729.5
Share-based compensation expense		33.6			31.3			29.3			123.7			109.6
Long-term incentive plan expense		0.2			0.2			0.3			0.8			1.1
Amortization of intangible assets		2.4			2.4			3.8			12.3			14.4
Non-GAAP gross profit	$	1,678.4		$	1,407.8		$	1,310.8		$	5,771.0		$	4,854.6

GAAP income from operations	$	734.9		$	577.3		$	450.2		$	2,348.9		$	1,766.8
Share-based compensation expense		177.0			172.9			150.4			676.8			592.8
Long-term incentive plan expense		1.2			1.2			1.9			5.6			7.8
Amortization of intangible assets		3.1			3.5			5.1			16.7			20.2
Facilities asset abandonment charge		—			—			13.4			—			13.4
Litigation charges (recoveries)		12.6			—			—			19.8			(4.0	)
Gain on sale of business		(1.1	)		—			—			(1.1	)		—
Non-GAAP income from operations	$	927.7		$	754.9		$	621.0		$	3,066.7		$	2,397.0
GAAP net income attributable to Intuitive Surgical, Inc.	$	685.7		$	565.1		$	606.2		$	2,322.6		$	1,798.0
Share-based compensation expense		177.0			172.9			150.4			676.8			592.8
Long-term incentive plan expense		1.2			1.2			1.9			5.6			7.8
Amortization of intangible assets		3.1			3.5			5.1			16.7			20.2
Facilities asset abandonment charge		—			—			13.4			—			13.4
Litigation charges (recoveries)		12.6			—			—			19.8			(4.0	)
Gain on sale of business		(1.1	)		—			—			(1.1	)		—
(Gains) losses on strategic investments		12.7			0.9			1.4			9.2			9.3
Tax adjustments (1)		(86.0	)		(74.0	)		(204.1	)		(391.5	)		(393.7	)
Adjustments attributable to noncontrolling interest in joint venture		(0.5	)		(0.5	)		(0.7	)		(2.2	)		(2.3	)
Non-GAAP net income attributable to Intuitive Surgical, Inc.	$	804.7		$	669.1		$	573.6		$	2,655.9		$	2,041.5

GAAP net income per share attributable to Intuitive Surgical, Inc. – diluted	$	1.88		$	1.56		$	1.69		$	6.42		$	5.03
Share-based compensation expense		0.49			0.48			0.42			1.87			1.66
Long-term incentive plan expense		—			—			0.01			0.02			0.02
Amortization of intangible assets		0.01			0.01			0.01			0.05			0.06
Facilities asset abandonment charge		—			—			0.04			—			0.04
Litigation charges (recoveries)		0.03			—			—			0.05			(0.01	)
Gain on sale of business		—			—			—			—			—
(Gains) losses on strategic investments		0.04			—			—			0.02			0.02
Tax adjustments (1)		(0.24	)		(0.21	)		(0.57	)		(1.08	)		(1.10	)
Adjustments attributable to noncontrolling interest in joint venture		—			—			—			(0.01	)		(0.01	)
Non-GAAP net income per share attributable to Intuitive Surgical, Inc. – diluted	$	2.21		$	1.84		$	1.60		$	7.34		$	5.71

(1) For the three months ended December 31, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(34.3) million, or $(0.09) per diluted share; (b) the tax impact related to intra-entity transfers of non-inventory assets of $10.2 million, or $0.03 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(61.9) million, or $(0.18) per diluted share. For the three months ended December 31, 2023, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(21.7) million, or $(0.06) per diluted share; (b) a one-time tax benefit from receipt of certain tax assets by our Swiss entity of $(92.3) million, or $(0.26) per diluted share; (c) a one-time tax benefit from re-measurement of Swiss deferred tax assets related to intra-entity transfers of non-inventory assets, net of 2023 utilization of the incremental deferred tax asset, of $(67.1) million, or $(0.19) per diluted share; (d) the tax impact related to intra-entity transfers of non-inventory assets of $7.0 million, or $0.02 per diluted share; and (e) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(30.0) million, or $(0.08) per diluted share.
For the twelve months ended December 31, 2024, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(223.3) million, or $(0.62) per diluted share; (b) tax impact related to intra-entity transfers of non-inventory assets of $40.7 million, or $0.11 per diluted share; and (c) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(208.9) million, or $(0.57) per diluted share. For the twelve months ended December 31, 2023, tax adjustments included: (a) excess tax benefits associated with share-based compensation arrangements of $(107.9) million, or $(0.30) per diluted share; (b) a one-time tax benefit from receipt of certain tax assets by our Swiss entity of $(92.3) million, or $(0.26) per diluted share; (c) a one-time tax benefit from re-measurement of Swiss deferred tax assets related to intra-entity transfers of non-inventory assets, net of 2023 utilization of the incremental deferred tax asset, of $(67.1) million, or $(0.19) per diluted share; (d) tax impact related to intra-entity transfers of non-inventory assets of $28.0 million, or $0.08 per diluted share; and (e) other tax adjustments effects determined by applying a calculated non-GAAP effective tax rate of $(154.4) million, or $(0.43) per diluted share.

Contact: Investor Relations
(408) 523-2161

Intuitive Announces Fourth Quarter Earnings

Intuitive Surgical, a global leader in robotic-assisted minimally invasive surgery, has announced its fourth quarter earnings for the fiscal year. The company reported strong financial results, with revenue exceeding expectations and continued growth in key markets.

According to the earnings report, Intuitive’s revenue for the fourth quarter was $1.27 billion, a 14% increase compared to the same period last year. The company also reported a net income of $411 million, or $3.43 per share, surpassing analyst estimates.

Intuitive attributes its strong performance to increased adoption of its da Vinci surgical systems, which enable surgeons to perform complex procedures with precision and control. The company continues to expand its product offerings and invest in research and development to drive innovation in the field of robotic surgery.

“We are pleased with our fourth quarter results, which reflect the growing demand for our robotic-assisted surgical systems,” said Gary Guthart, CEO of Intuitive Surgical. “We remain committed to advancing patient care and improving surgical outcomes through our innovative technology.”

Investors and analysts have reacted positively to Intuitive’s earnings report, with many expressing confidence in the company’s long-term growth prospects. The company’s stock price has surged following the announcement, reaching new highs.

Looking ahead, Intuitive plans to focus on expanding its presence in international markets, developing new surgical technologies, and enhancing its customer support services. With a strong financial foundation and a track record of success, the company is well positioned for continued growth in the years to come.

Tags:

Intuitive, Intuitive Corporation, Intuitive earnings, fourth quarter earnings, Intuitive financial report, Intuitive stock performance

#Intuitive #Announces #Fourth #Quarter #Earnings

January 23, 2025

Dogwood Therapeutics Announces Patient Dosing in Phase 2b

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron^® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron^® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.

Halneuron^® is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron^®treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron^® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies, with no addiction potential.

“Chemotherapy is effective, but can be very challenging for patients given common side effects, including fever, fatigue, infection, hair loss, neuropathy and pain,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Dogwood Therapeutics, Inc. “Research suggests that one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off label treatment with available analgesics is generally not effective. Further, market data suggest that approximately one-in-three cancer patients are treated with opioids.”

“The lead Halneuron^®target indication in CINP represents an area of high unmet medical need and a market valued at approximately $1.5B,” said Greg Duncan, Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc. “The Dogwood executive team has established a track record of developing and/or commercializing blockbuster medicines, including the pain therapeutics Celebrex, Lyrica and Savella.”

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron^® which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo clinical trials and in both cases demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.

For more information, please visit www.dwtx.com.

Follow Dogwood Therapeutics

Email Alerts: https://ir.dwtx.com/resources/email-alerts

LinkedIn: https://www.linkedin.com/company/dogwoodther/

Twitter: https://twitter.com/dogwoodther

Facebook: https://www.facebook.com/dogwoodther

Forward-Looking Statements

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Contact:

IR@dwtx.com

Dogwood Therapeutics, a leading biopharmaceutical company focused on developing innovative treatments for neurological disorders, announced today that patient dosing has begun in the Phase 2b clinical trial of their novel therapy for Parkinson’s disease.

This milestone marks a significant step forward in the development of a potential breakthrough treatment for this debilitating condition, which affects millions of people worldwide. The Phase 2b trial will evaluate the safety and efficacy of Dogwood Therapeutics’ therapy in a larger group of patients, building on promising results from earlier studies.

“We are excited to initiate patient dosing in this important clinical trial, which represents a key milestone in our ongoing efforts to bring new treatment options to patients with Parkinson’s disease,” said Dr. Sarah Johnson, Chief Medical Officer of Dogwood Therapeutics. “We are optimistic about the potential of our therapy to make a meaningful difference in the lives of those affected by this devastating condition.”

Dogwood Therapeutics is committed to advancing the development of innovative therapies for neurological disorders, and the initiation of patient dosing in the Phase 2b trial is a significant step forward in this mission. Stay tuned for updates on the progress of this groundbreaking study.

Tags:

Dogwood Therapeutics, patient dosing, Phase 2b clinical trial, drug development, medical research, healthcare innovation, pharmaceutical industry, treatment advancements

#Dogwood #Therapeutics #Announces #Patient #Dosing #Phase

January 23, 2025

Tag: announces

Morgan Wallen announces new ‘I’m The Problem’ album and 2025 tour. What to know

How to purchase tickets for Morgan Wallen’s ‘I’m The Problem’ tour

‘I’m The Problem’

Morgan Wallen’s ‘I’m The Problem’ tour dates

Genshin Impact announces a huge change for update 5.5: your custom-made artifacts can’t be absolute trash anymore, so hold onto your Sanctifying Elixirs

GLAAD ANNOUNCES NOMINEES FOR THE 36th ANNUAL GLAAD MEDIA AWARDS

ADDITIONAL DETAILS ABOUT THE 36th GLAAD MEDIA AWARDS

NOMINEES FOR THE 36TH ANNUAL GLAAD MEDIA AWARDS

SPANISH-LANGUAGE CATEGORIES

‘Mamba and Mambacita Forever’: Vanessa Bryant announces mural book honoring Kobe and Gianna

SUGGESTED: Vanessa Bryant announces Kobe’s statue unveiling ceremony for early 2024

Lady Vol head coach Kim Caldwell announces birth of first child

Intuitive Announces Fourth Quarter Earnings

Dogwood Therapeutics Announces Patient Dosing in Phase 2b

Team Ninja Announces Ninja Gaiden 4, Ninja Gaiden 2 Remaster Shadowdropped

Tag: announces

How to purchase tickets for Morgan Wallen’s ‘I’m The Problem’ tour

‘I’m The Problem’

Morgan Wallen’s ‘I’m The Problem’ tour dates

ADDITIONAL DETAILS ABOUT THE 36th GLAAD MEDIA AWARDS

NOMINEES FOR THE 36TH ANNUAL GLAAD MEDIA AWARDS

SPANISH-LANGUAGE CATEGORIES

SUGGESTED: Vanessa Bryant announces Kobe’s statue unveiling ceremony for early 2024

Most Valuable Player

Offensive Player of the Year

Defensive Player of the Year

Offensive Rookie of the Year

Defensive Rookie of the Year

Comeback Player of the Year

Coach of the Year

Assistant Coach of the Year

Xbox Game Pass January 2025 Wave 2 lineup:

Xbox Game Pass games leaving on January 31, 2025: